In 2015, after a median follow up period of 4 yr, adjuvant PTX and TTZ combination treatment trials reported that the 3 yr disease-free survival rate was 98.7% in HER2 positive breast cancer patients26. This evidence concerns the gene ERBB2 and breast carcinoma.